Share prices of Cipla gained 2.5 per cent in the early trade on Monday after USFDA issued zero observation for its Indore facility.
At the company’s Indore facility, United States Food and Drug Administration (USFDA) conducted a post-approval inspection from May 13 to May 17, 2019, and said that the inspection ended with zero observations.
The share touched the 52 week high Rs 678 and 52 week low Rs 483.75 on 19th September 2018 and 29 January 2019, respectively.
At 09:42 hrs Cipla was quoting at Rs 555.10, up to Rs 11.15, or 2.05 per cent on the BSE. Currently, it is trading 18.13 per cent below its 52-week high and 14.74 per cent above its 52-week low.